A New Biomarker for Fetal Growth Restriction and Neonatal Risk
A prospective case-control study from Turkey has identified a significant link between reduced osteopontin levels and fetal growth restriction (FGR). Researchers compared 40 women with FGR pregnancies to 40 healthy controls, collecting maternal serum and placental tissue at delivery. The results showed that both maternal serum and placental osteopontin concentrations were markedly lower in the FGR group. Notably, placental osteopontin, when normalized to total protein, demonstrated the best predictive performance for identifying FGR, with a sensitivity of 77.5% and specificity of 70.0%. Furthermore, lower osteopontin levels were also predictive of composite adverse neonatal outcomes, suggesting this protein could serve as a valuable clinical biomarker.
Why it might matter to you: This research directly addresses the critical need for better predictive tools in prenatal care and high-risk pregnancy management. For clinicians, a reliable biomarker like osteopontin could enhance antenatal screening protocols, allowing for earlier identification of placental insufficiency and more targeted fetal monitoring. Incorporating such molecular insights could refine risk stratification, inform decisions regarding the timing of delivery, and ultimately improve strategies to mitigate adverse neonatal outcomes associated with FGR.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
